EP Patent

EP3135296A1 — Medicine against growth impairment induced by administration of steroid

Assigned to Daiichi Sankyo Co Ltd · Expires 2017-03-01 · 9y expired

What this patent protects

Provided is a medicine for reducing and/or ameliorating growth failure induced by the administration of a steroid during a growth period, the medicine containing at least one type of natriuretic peptide receptor B (NPR-B) agonist as an active ingredient.

USPTO Abstract

Provided is a medicine for reducing and/or ameliorating growth failure induced by the administration of a steroid during a growth period, the medicine containing at least one type of natriuretic peptide receptor B (NPR-B) agonist as an active ingredient.

Drugs covered by this patent

Patent Metadata

Patent number: EP3135296A1
Jurisdiction: EP
Classification: —
Expires: 2017-03-01
Drug substance claim: No
Drug product claim: No
Assignee: Daiichi Sankyo Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.